Allogeneic mixed lymphocyte reactions during a second round of ontogeny: normal accessory cells did not restore defective interleukin-2 (IL-2) synthesis in T cells but induced responsiveness to exogeneous IL-2.

The T-cell-accessory-cell interaction in mixed lymphocyte cultures was investigated in 25 patients following autologous bone marrow transplantation (ABMT) using autologous bone marrow treated in vitro with the cyclophosphamide derivative ASTA Z 7557. In a previous study using the same group of patients, T cells failed to synthesize interleukin-2 (IL-2) and proliferate in response to CD3- and CD2-mediated stimuli even in the presence of exogenous IL-2. To investigate whether this defect in IL-2 synthesis and proliferation was caused by defective cell-to-cell interactions, we analyzed mixed lymphocyte reactions (MLR) using T cells and irradiated non-T cells. When normal T cells from 10 different healthy subjects were challenged with allogeneic normal non-T cells, IL-2 production and proliferation were observed. In contrast, when normal T cells were cultured with non-T cells derived from patients found between 20 and 330 days after ABMT, no IL-2 secretion and no proliferative responses could be seen. The addition of lymphokines such as interleukin-1 (IL-1), interleukin-3 (IL-3), tumor necrosis factor (TNF), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon-gamma (IFN-y) did not improve the reactions. Furthermore, when patients' T cells were incubated with normal, irradiated non-T cells, defective IL-2 synthesis or proliferative response was obtained. However, when IL-2 was added to these cultures, an improvement in proliferative reactions was observed. Taken together, these new data provide additional evidence that T cells early in ontogeny possessed an intrinsic defect in IL-2 synthesis and that physical cell-to-cell contact between patients' T cells and allogeneic accessory cells induced functional responsiveness to exogeneous IL-2.

[1]  L. Samelson,et al.  Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56lck , 1989, Nature.

[2]  N. Tonks,et al.  CD45 regulates signal transduction and lymphocyte activation by specific association with receptor molecules on T or B cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[3]  B. Haynes,et al.  A novel activation pathway for mature thymocytes. Costimulation of CD2 (T,p50) and CD28 (T,p44) induces autocrine interleukin 2/interleukin 2 receptor-mediated cell proliferation , 1988, The Journal of experimental medicine.

[4]  B. Dörken,et al.  B-cell proliferative and differentiative responses after autologous peripheral blood stem cell or bone marrow transplantation. , 1988, Blood.

[5]  Charles A. Janeway,et al.  Receptor-directed focusing of lymphokine release by helper T cells , 1988, Nature.

[6]  Y. Humblet,et al.  Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation. , 1987, Experimental hematology.

[7]  S. Meuer,et al.  Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. , 1987, The Journal of clinical investigation.

[8]  C. Nathan,et al.  Secretory products of macrophages. , 1987, The Journal of clinical investigation.

[9]  M. López-Botet,et al.  Defective interleukin 2 receptor expression is associated with the T cell disfunction subsequent to bone marrow transplantation , 1987, European journal of immunology.

[10]  R. Brookmeyer,et al.  Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. , 1985, Blood.

[11]  R. Mertelsmann,et al.  Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. , 1984, Blood.

[12]  J. Adams,et al.  Role of interleukin-2 in depressed T-cell mitogenesis after allogeneic marrow transplantation in man. , 1984, Leukemia research.

[13]  J. Biggs,et al.  Human bone marrow allograft recipients: production of, and responsiveness to, interleukin 2. , 1983, Journal of immunology.

[14]  R. Storb,et al.  Impaired autologous and allogeneic mixed lymphocyte reaction in human marrow transplant recipients. , 1983, Experimental hematology.

[15]  W. Falk,et al.  Activation of cytotoxic T lymphocytes requires at least two spleen cell-derived helper factors besides interleukin 2. , 1983, Journal of immunology.

[16]  R. Storb,et al.  Cellular interactions in marrow-grafted patients. I. Impairment of cell-mediated lympholysis associated with graft-vs-host disease and the effect of interleukin 2. , 1983, Journal of immunology.

[17]  D. Linch,et al.  T cell regeneration after allogeneic and autologous bone marrow transplantation , 1982, British journal of haematology.

[18]  M. Körbling,et al.  4‐Hydroperoxyclophosphamide: a model for eliminating residual human tumour cells and T‐lymphocytes from the bone marrow graft , 1982, British journal of haematology.

[19]  R. Storb,et al.  Nonspecific suppressor cells in patients with chronic graft-vs-host disease after marrow grafting. , 1979, Journal of immunology.

[20]  H. Ochs,et al.  Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. , 1978, Blood.

[21]  M. R. Mickey,et al.  Immunodeficiency following allogeneic bone marrow transplantation. , 1978, Transplantation proceedings.

[22]  S. Ferrone,et al.  Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. , 1975, Clinical immunology and immunopathology.